CHINARES PHARMA Raises RMB0.90 Billion via Second-Tranche 2026 Bond, Fixed Coupon at 1.48%

Bulletin Express10-16

China Resources Pharmaceutical Group Limited (abbreviated as CHINARES PHARMA) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the public issuance of the second tranche of its 2026 corporate bonds in mainland China.

The issuance raised RMB0.90 billion through three-year bonds carrying a fixed annual coupon of 1.48%. According to the filing, net proceeds will be allocated to production spending, repayment of existing debt, working-capital replenishment, project development and operational outlays, as well as investments in scientific and technological innovation, all in compliance with relevant regulations.

Management reiterated that shareholders and potential investors should exercise caution when trading the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment